Given the emerging evidence for CDK9’s cancer-promoting activity [71] and its over-expression in prostate cancer, we investigated the therapeutic utility of an orally deliverable CDK9 inhibitor, CDKI-73. Here, CDK9 is linked to prostate carcinoma.